John Sarantopoulos

5.2k total citations · 1 hit paper
143 papers, 3.2k citations indexed

About

John Sarantopoulos is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John Sarantopoulos has authored 143 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Oncology, 55 papers in Molecular Biology and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John Sarantopoulos's work include Cancer Treatment and Pharmacology (37 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Lung Cancer Treatments and Mutations (18 papers). John Sarantopoulos is often cited by papers focused on Cancer Treatment and Pharmacology (37 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Lung Cancer Treatments and Mutations (18 papers). John Sarantopoulos collaborates with scholars based in United States, Japan and Switzerland. John Sarantopoulos's co-authors include Devalingam Mahalingam, Alain C. Mita, Monica Mita, Anthony W. Tolcher, Kamalesh K. Sankhala, Tyler J. Curiel, Francis J. Giles, Jordi Rodón, Chia‐Chi Lin and Andrew Brenner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

John Sarantopoulos

141 papers receiving 3.1k citations

Hit Papers

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 A... 2021 2026 2022 2024 2021 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
    2021 257 citations Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Sarantopoulos United States 28 1.6k 1.3k 528 443 413 143 3.2k
Argun Akçakanat United States 26 1.4k 0.9× 1.4k 1.1× 525 1.0× 600 1.4× 253 0.6× 52 2.9k
Igor Astsaturov United States 32 1.2k 0.8× 1.1k 0.9× 496 0.9× 339 0.8× 255 0.6× 97 2.7k
Makoto Saegusa Japan 38 1.8k 1.1× 1.3k 1.0× 565 1.1× 460 1.0× 484 1.2× 163 3.8k
Young Hwa Soung South Korea 30 2.3k 1.4× 1.2k 0.9× 621 1.2× 262 0.6× 260 0.6× 70 3.2k
Edgar Selzer Austria 35 1.7k 1.1× 951 0.7× 360 0.7× 604 1.4× 213 0.5× 106 3.7k
Olivier Dormond Switzerland 33 1.7k 1.1× 1.1k 0.9× 323 0.6× 422 1.0× 182 0.4× 72 3.3k
Wei Yuan China 32 1.2k 0.8× 882 0.7× 399 0.8× 912 2.1× 279 0.7× 106 2.9k
Ben Markman Australia 24 1.3k 0.8× 1.2k 0.9× 489 0.9× 219 0.5× 238 0.6× 75 2.5k
Emiliano Cocco United States 32 1.1k 0.7× 1.6k 1.2× 833 1.6× 294 0.7× 193 0.5× 83 3.2k
Alessia Ciarrocchi Italy 33 2.4k 1.5× 1.2k 0.9× 639 1.2× 272 0.6× 286 0.7× 115 4.0k

Countries citing papers authored by John Sarantopoulos

Since Specialization
Citations

This map shows the geographic impact of John Sarantopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Sarantopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Sarantopoulos more than expected).

Fields of papers citing papers by John Sarantopoulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Sarantopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Sarantopoulos. The network helps show where John Sarantopoulos may publish in the future.

Co-authorship network of co-authors of John Sarantopoulos

This figure shows the co-authorship network connecting the top 25 collaborators of John Sarantopoulos. A scholar is included among the top collaborators of John Sarantopoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Sarantopoulos. John Sarantopoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meric‐Bernstam, Funda, Martin Gutierrez, Enrique Sanz‐García, et al.. (2025). Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer Research Communications. 5(9). 1664–1673. 1 indexed citations
2.
Subbiah, Vivek, Irene Braña, Alessandra Longhi, et al.. (2022). Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clinical Cancer Research. 28(13). 2762–2770. 18 indexed citations
3.
Curigliano, Giuseppe, Hans Gelderblom, Nicolas Mach, et al.. (2021). Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research. 27(13). 3620–3629. 257 indexed citations breakdown →
4.
Tsimberidou, Apostolia M., Dejan Juric, Claire F. Verschraegen, et al.. (2021). Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. Journal of Hematology & Oncology. 14(1). 127–127. 20 indexed citations
5.
Mahalingam, Devalingam, Manish R. Patel, Jasgit C. Sachdev, et al.. (2020). Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. British Journal of Clinical Pharmacology. 86(9). 1836–1848. 49 indexed citations
6.
Mahalingam, Devalingam, Judy S. Wang, Erika Hamilton, et al.. (2019). Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. Clinical Cancer Research. 25(12). 3508–3516. 47 indexed citations
7.
Grande, Enrique, R. Donald Harvey, Benoît You, et al.. (2019). Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. Journal of Pharmacology and Experimental Therapeutics. 369(2). 291–299. 15 indexed citations
8.
Mahalingam, Devalingam, Christos Fountzilas, Jennifer L. Moseley, et al.. (2017). A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemotherapy and Pharmacology. 79(4). 697–703. 68 indexed citations
9.
Sarantopoulos, John, Geoffrey I. Shapiro, Roger B. Cohen, et al.. (2015). Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(4). 847–857. 139 indexed citations
10.
Rodón, Jordi, Hussein Tawbi, Anne Thomas, et al.. (2014). A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(7). 1900–1909. 187 indexed citations
11.
Mahalingam, Devalingam, Laeeq Malik, Muralidhar Beeram, et al.. (2014). Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemotherapy and Pharmacology. 74(1). 77–84. 24 indexed citations
12.
Lockhart, A. Craig, John Sarantopoulos, Monica Mita, et al.. (2014). Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors. Investigational New Drugs. 32(6). 1236–1245. 8 indexed citations
13.
Rosen, Lee S., Igor Puzanov, Gregory Friberg, et al.. (2012). Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(12). 3414–3427. 30 indexed citations
14.
Mita, Monica, Yubao Wang, John Sarantopoulos, et al.. (2011). Abstract B55: A study of REOLYSIN in combination with gemcitabine in patients with advanced pancreatic adenocarcinoma.. Molecular Cancer Therapeutics. 10(11_Supplement). B55–B55. 3 indexed citations
15.
Kauh, John, Roger B. Cohen, R. Donald Harvey, et al.. (2009). Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin. Journal of Clinical Oncology. 27(15_suppl). 2562–2562. 4 indexed citations
16.
Mita, Monica, Alain C. Mita, John Sarantopoulos, et al.. (2008). Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 64(2). 287–295. 23 indexed citations
17.
Batist, Gerald, John Sarantopoulos, Kamalesh K. Sankhala, et al.. (2007). A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease. Molecular Cancer Therapeutics. 6. 1 indexed citations
18.
Sankhala, Kamalesh K., Alain C. Mita, Alejandro D. Ricart, et al.. (2007). A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors. Molecular Cancer Therapeutics. 6. 2 indexed citations
19.
Sarantopoulos, John, et al.. (2006). 359 POSTER Pharmacokinetic and pharmacodynamic effects of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors. European Journal of Cancer Supplements. 4(12). 111–112. 1 indexed citations
20.
Preston, Gavin, Christopher B. Jones, John Sarantopoulos, et al.. (2006). Phase I study of the effects of hepatic impairment on the pharmacokinetic (PK) and safety of satraplatin in patients with refractory non-hematologic cancer. Journal of Clinical Oncology. 24(18_suppl). 2045–2045. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Argun Akçakanat Breakdown of academic impact, for papers by Igor Astsaturov Breakdown of academic impact, for papers by Makoto Saegusa Breakdown of academic impact, for papers by Young Hwa Soung Breakdown of academic impact, for papers by Edgar Selzer Breakdown of academic impact, for papers by Olivier Dormond Breakdown of academic impact, for papers by Wei Yuan Breakdown of academic impact, for papers by Ben Markman Breakdown of academic impact, for papers by Emiliano Cocco Breakdown of academic impact, for papers by Alessia Ciarrocchi
Rankless by CCL
2026